Insights: Publications Drug to Biologic Transition: Is Purple The New Orange?

Kilpatrick Townsend MEMO|Biopharma Industry Blog

Written by Yifan Mao
The regulatory approval pathway for a new “biological product” submitted as a Biologics License Application (BLA) under the Biologics Price Competition and Innovation Act (BPCIA), is now separate from the approval process for a new “drug” product submitted as a New Drug Application (NDA) under the Hatch-Waxman Act. Two separate searchable online databases now exist for approved “drug” and “biological” products, respectively; the Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), and the Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations (Purple Book).

Related People

close
Loading...
If you would like to receive related insights and information from Kilpatrick Townsend, please provide your contact details by filling out the form and clicking “Agree.” If you would like to access the PDF only, please click “Download Only.”